RxDoctor Payments Data

Colleen Adkins, MD

Allergy & Immunology · Austin, TXNPI 1689991879

Payments from drug & device makers

$2,569in general payments, 2019–2025

Across 84 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$647
  • Regeneron Healthcare Solutions, Inc.$473
  • AstraZeneca$340
  • Amgen$191
  • Welch Allyn$186
  • Galderma Laboratories, L.p.$128
  • plus $605 from 13 others

What the payments were for

  • Food & beverage$2,33791%
  • Education$462%
  • Other$1867%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,569 in reported general payments places this provider in the 30th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$38,193
Medicare patients
130
Services billed
2,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$86,444
NucalaMepolizumab13$41,654
Breo ElliptaFluticasone/Vilanterol28$20,738
Azelastine Hcl198$4,910
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$4,886
Wixela InhubFluticasone Propion/Salmeterol13$3,899
SymbicortBudesonide/Formoterol Fumarate13$3,306
Ipratropium Bromide101$3,092
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,703
Epinephrine11$2,155
Montelukast Sodium118$1,600
Mometasone Furoate14$1,479
Albuterol Sulfate HfaAlbuterol Sulfate56$1,396
Fluticasone Propionate57$696
Zafirlukast13$646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta$647$148,836110 claims
AstraZenecaSymbicort$340$3,30613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →